Skip to main content

Select Drug Profiles

Practice Management

Transforming the Drug Cost Paradigm from Payment for Medications to Payment for Value

William Fleming, PharmD

Practice Management

Healthcare Utilization and Costs of Knee or Hip Replacements versus Pain-Relief Injections

Margaret K. Pasqule, PhD, Anthony M. Louder, PhD, RPh, Raymond Y. Cheung, PhD, Andrew T. Reiners, MD, Robert J. Sanchez, PhD, Veerainder Goli, MD, MBA, DFAPA, Jack Mardekian, PhD

Stakeholder Perspective

Knee and Hip Pain: Rewarding Optimal Long-Term Management

by Steve Miff, PhD

Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder

Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer

The Continuing Clinical and Economic Burden of Cardiometabolic Health

Dalia Buffery, MA, ABD

Compensation for Managing Population Health

David B. Nash, MD, MBA

Original Research

Longitudinal Commercial Claims–Based Cost Analysis of Diabetic Retinopathy Screening Patterns

Kathryn Fitch, RN, MEd, Thomas Weisman, MD,MBA, Tyler Engel, ASA, MAAA, Adam Turpcu, PhD, Helen Blumen, MD, MBA, Yamina Rajput, MS, Purav Dave, MS, MBA

Stakeholder Perspective

The Economics of Screening Patients with Diabetes for Diabetic Retinopathy

by Sharon Glave Frazee, PhD, MPH

Practice Management

Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus

Janice M.S. Lopez, PharmD, MPH, Brian Macomson, PharmD, Varun Ektare, MPH, Dipen Patel, PhD, Marc Botteman, MSc

Stakeholder Perspective

Evaluating the Benefits and Cost of the Sodium-Glucose Cotransporter 2 Inhibitors

by Quang T. Nguyen, DO, FACE, FTOS

Practice Management

The Impact of HbA1c Testing on Total Annual Healthcare Expenditures Among Newly Diagnosed Patients with Diabetes

Prajakta Bhounsule, MS, Andrew M. Peterson, PharmD, PhD

Stakeholder Perspective

Saving Money Is Not Always the Objective

by Gary M. Owens, MD

Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure

Page 126 of 244
Results 1251 - 1260 of 2434